Press Release
SoluLinK, Incorporated
9853
Pacific Heights Blvd. Suite H,
San Diego, California 92121
Phone: 858.625.0670
Fax: 858.625.0770
solulink@solulink.com
SoluLinK
Forms Scientific Advisory Board
SAN DIEGO, California. -
October 16, 2006 - SoluLinK, The Conjugation CompanyTM,
announced the formation of a Scientific Advisory Board (SAB)
to oversee the research, development, and commercialization
of SoluLinK’s next generation of vertically integrated
bioconjugation, detection, and immobilization products.
SoluLink is pleased to have the expertise of these accomplished
professionals on its SAB:
David C. Ward, Ph.D.,
Deputy Director, Nevada Cancer Institute
Dr. Ward is internationally recognized for his pioneering research
in the fields of molecular cytogenetics, cancer genetics, virology,
and optical imaging technology. He has received numerous national
and international awards, including election to the National
Academy of Sciences of the USA. He has co authored over 300
scientific publications and has served on grant review panels
in the US, Canada, and England for many years. Dr Ward is also
a co founder of five biotechnology companies, three of which
are publicly traded on national stock exchanges.
Matt Francis, Ph.D.,
Assistant Professor, UC Berkeley
Research in Dr. Francis’ group at UC Berkeley is focused
on the development of new synthetic methods for the construction
of nanoscale materials. The central strategy involves the attachment
of new functional components to specific locations on structural
proteins, and the subsequent self-assembly of these conjugates
into new types of materials with useful electronic and biological
functions.
Bob D. Brown, Ph.D., Vice President,
Research and Technology, Genta, Inc.
Dr. Brown heads discovery research and new technology evaluations.
He has studied gene expression at the RNA level for 20 years
and has over 75 patents and patent applications. He has led
therapeutic research programs from proof-of-principle models
through in vivo efficacy demonstrations to support IND filings,
including key development work on Genasense™. Dr. Brown
was co-founder and Vice President of Research and Development
at Oasis Biosciences. He holds a Ph.D. in Molecular Biology
from the University of California, Berkeley and a B.S. in Chemistry
and a B.S. in Biology from the University of Washington.
Martin Latterich, Ph.D., Associate
Professor, McGill University; Canada Research Chair in Cellular
Membrane Dynamics
Dr. Latterich worked at Diversa and Illumina Inc., both in San
Diego, prior to accepting a position at McGill University in
Montreal, Canada and is now a leading native Canadian researcher
in the field of proteomics. Dr Latterich’s work addresses
fundamental questions in cell biology which are relevant to
diseases such as cancer, neurodegeneration, Werner syndrome,
and myopathy. His laboratory uses techniques that combine genetics
with biochemistry, cell biology, and proteomics to address the
molecular mechanisms that result in specific membrane fusion
events, dynamic protein complex assembly, and disassembly reactions.
C. Satishchandran, Ph.D., Senior
Vice President Research and Development, Nucleonics Inc., Horsham,
PA
Dr. Satishchandran was the Senior Research Fellow and Associate
Director of Gene Expression and Delivery at Appolon, Inc, prior
to its acquisition by Wyeth-Ayerst in 1998. Following the acquisition,
he became the Acting Director of DNA Vaccines until he left
recently to pursue his interests at PTGS at Thomas Jefferson
University. Dr. Satischcnadran’s research programs at
Apollon, Wyeth, and Nucleonics have resulted in several patents
and publications. The DNA vaccine program at Appolon and Wyeth
resulted in the initiation of six clinical programs, two of
which are currently in Phase I/II. Prior to joining Apollon,
he was a member of the Biophysics group at Forx Chase Cancer
Center in Philadelphia. He received his Ph.D. in Molecular Biology
and Biochemistry from Memorial University of Newfoundland, Canada.
“Each of these distinguished scientists
are leaders in their fields of molecular biology, proteomics,
chemistry, diagnostics and therapeutics,” said David Schwartz,
SoluLinK’s CEO and CSO. “We are honored that they
have agreed to serve as members of SoluLinK’s Scientific
Advisory Board. The new advisory board’s expertise will
be an immensely valuable resource in developing and commercializing
SoluLinK’s superior technologies,” added Dr. Schwartz
About SoluLinK
SoluLinK is a leader in the development of advanced biological
reagents and custom services for the life sciences, diagnostic,
and nanotechnology research communities. Specifically, SoluLinK
(a privately-held company located in San Diego, California)
develops, manufactures, and markets bioconjugation products
and services. SoluLink’s proprietary bioconjugation linking
chemistry is used to link proteins, oligonucleotides, peptides,
and antibodies to each other or to a wide range of surfaces.
A rapidly growing application for SoluLink’s linking technology
include conjugation of biomolecules to solid surfaces for diagnostic,
therapeutic, and/or microarray products. SoluLinK’s proprietary
biotinylation reagent ChromaLink® Biotin is one more example
of a new product that is helping to enhance the performance
of more defined biotin-antibody conjugates used by a wide spectrum
of customers. SoluLinK markets these products directly and through
distributors/licensing partners, world-wide.
For
more information, please contact Solulink directly:
SoluLinK - The Conjugation Company
9853 Pacific Heights Blvd. Suite H,
San Diego, California 92121
Toll Free: 888.625.0670
Phone: 858.625.0670
Fax: 858.625.0770
solulink@solulink.com |
